Molecular Partners Archives

News and Trends 30 May 2023

Molecular Partners presenting positive solid tumor data

Molecular Partners AG will present additional positive data from the ongoing phase 1 study of MP0317, a CD40 agonist designed to activate immune cells specifically within the tumor microenvironment by anchoring to fibroblast activation protein (FAP), at the 2023 ASCO (American Society of Clinical Oncology) annual meeting, June 2 to 6 in Chicago, U.S. The […]

May 30, 2023 - 4 minutesmins - By Jim Cornall

Molecular Partners drug development cancer

Interview 16 May 2019

Taking a Drug to Market “Is a Marathon, Not a Sprint”

Based in Zurich, Molecular Partners is developing a new class of drugs that can address the complexity of cancer. At Labiotech Refresh in Zurich, CEO Patrick Amstutz shared what he’s learned on the journey to take the company where it is today. After completing a PhD at ETH Zurich, Amstutz founded Molecular Partners with a […]

May 16, 2019 - 4 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 15 Mar 2017

What are the Best Countries to Recruit Biotech Talents in 2017?

Before the “who to recruit” phase, an important question is “where?” We ran through the top countries in which to look for talent in biotech and had a look at what you can expect from each cluster. For each one of them, we also referenced some data on the biotech, life science and research ecosystems to […]

March 15, 2017 - 10 minutesmins - By External Contributor

News and Trends 11 Jul 2016

How to build a Successful Biotech company in Europe with Joern Aldag

Joern Aldag is one of the impressive Biotech leaders in Europe. Hearing him at our Refresh conference made me think of a new type of article we could publish: a detailed summary of the lessons learned from such a very rich career. Here’s the first of such a piece. Aldag was just appointed CEO of […]

July 11, 2016 - 6 minutesmins - By Philip Hemme

zurich biotech octapharma ehtz switzerland

News and Trends 7 Jun 2016

Zurich is not all about Money – here are 9 Biotechs proving it!

The biggest city in Switzerland, Zurich, is one of Europe’s top financial centers and home to the SIX Swiss Exchange (SWX). It’s also one of the most expensive cities in Europe to live in (as my Swiss colleague Claire could confirm). With so much money nearby, how does the local Biotech ecosystem looks like? The biggest Biotech/mid-size Pharma in […]

June 7, 2016 - 5 minutesmins - By Denise Neves Gameiro

News and Trends 4 Apr 2016

Biotech Environment in 2016: Reverse Engineering the Ecosystem #BES2016

BIO-Europe Spring 2016 is starting off right away with the plenary opening session. The conference was about partnering, trends and opinion from both Biotechs and Pharma… This was the list of pretty impressive speakers: How are Big Pharma positioning themselves in 2016? J&J clearly wants to open up more to the outside of the organisation, […]

April 4, 2016 - 5 minutesmins - By Philip Hemme

News and Trends 27 Jul 2015

Roche exits €940M discovery alliance with Molecular Partners

Roche left the collaboration with Molecular Partners, walking away from a potential cancer treatment using the DARPin technology. The collaboration, entered in 2013, was worth up to €940M. Molecular Partners is a Swiss company focusing on immuno-oncology. The company has developed a platform generating small proteins called DARPins (Designed Ankyrin Repeat Proteins). These can target […]

July 27, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 6 Feb 2015

2014, the Biggest Year Ever for European Biotech IPOs

There is no need to say it: biotechnology is the latest trend. A worldwide bio-boom has shaken stock markets throughout 2014. For European start-ups, last year represented a remarkable step forward as 15 companies went public and raised €719.8M in total, as Biocom’s last report states. Let me present you a review summering the major […]

February 6, 2015 - 3 minutesmins - By Lourdes Riquelme

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us